APA (7th ed.) Citation

Thol, F., & Schlenk, R. F. (2018). Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML. Blood, 132(16), . https://doi.org/10.1182/blood-2018-02-829911

Chicago Style (17th ed.) Citation

Thol, Felicitas, and Richard Friedrich Schlenk. "Measurable Residual Disease Monitoring by NGS Before Allogeneic Hematopoietic Cell Transplantation in AML." Blood 132, no. 16 (2018). https://doi.org/10.1182/blood-2018-02-829911.

MLA (9th ed.) Citation

Thol, Felicitas, and Richard Friedrich Schlenk. "Measurable Residual Disease Monitoring by NGS Before Allogeneic Hematopoietic Cell Transplantation in AML." Blood, vol. 132, no. 16, 2018, https://doi.org/10.1182/blood-2018-02-829911.